This company’s synthetic bone-graft material promises orthopaedic surgeons “more bone in less time”. The reported advantages of its product Actifuse in operations such as spinal fusion or trauma repair include faster and higher-quality bone formation, and there is no risk of infection as with bones donated by other patients. Based on research and intellectual property from London and Cambridge universities, Apatech has raised £11.5m in private equity from 3i and MTI Partners and £3.5m of debt from Noble Ventures. The Hertfordshire company, headed by Simon Cartmell, sells more than 1,000 packs of its product a month to public and private hospitals in 20 countries. Sales increased 238% a year from £270,000 in 2005 to £3.1m in 2007.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.